<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="7069936174 doi: 10.1038/s41541-020-0174-9 : Article Efficacy of FLU-v, a broad-spectrum" exact="influenza" post="vaccine, in a randomized phase IIb human influenza challenge"/>
 <result pre="a broad-spectrum influenza vaccine, in a randomized phase IIb human" exact="influenza" post="challenge study http://orcid.org/0000-0002-7099-5002PleguezuelosOlga1http://orcid.org/0000-0002-4031-4210JamesEmma1FernandezAna1LopesVictor2RosasLuz Angela3Cervantes-MedinaAdriana4http://orcid.org/0000-0002-3521-6122CleathJason4EdwardsKristina4NeitzeyDana4GuWenjuan5HunsbergerSally5TaubenbergerJeffery K.3StoloffGregory1MemoliMatthew J.memolim@niaid.nih.gov4[1], [2], [3], 0000"/>
 <result pre="aiming to provide a broadly protective cellular immune response against" exact="influenza" post="A and B. A randomized, double-blind, placebo-controlled, single-center, phase"/>
 <result pre="to intranasal challenge on day 0 with the A/California/04/2009/H1N1 human" exact="influenza" post="A challenge virus. The primary objective of the study"/>
 <result pre="study was to identify a reduction in mild to moderate" exact="influenza" post="disease (MMID) defined as the presence of viral shedding"/>
 <result pre="(MMID) defined as the presence of viral shedding and clinical" exact="influenza" post="symptoms. Single-dose adjuvanted FLU-v recipients (n = 40) were significantly less"/>
 <result pre="and mortality associated with yearly epidemics and sporadic pandemics. Seasonal" exact="influenza" post="is estimated to cause up to 79,400 deaths in"/>
 <result pre="is the primary method available to mitigate the effect of" exact="influenza" post="on the world’s population. Current vaccines rely on specific"/>
 <result pre="involved in killing and removing cells that are infected with" exact="influenza" post="viruses9–14. These cells may play an important role in"/>
 <result pre="cells may play an important role in the clearance of" exact="influenza" post="virus both before and after clinical symptoms appear. Influenza"/>
 <result pre="proteins aiming to provide a broadly protective immune response against" exact="influenza" post="A and B through viral clearance by cytotoxic T"/>
 <result pre="with reduction of viral shedding and reduced symptoms after H3N2" exact="influenza" post="challenge20,21. The objective of this study was to test"/>
 <result pre="Efficacy of FLU-v The highest rate of mild to moderate" exact="influenza" post="disease (MMID) was observed in the placebo group, with"/>
 <result pre="positive if a participant had at least one symptom of" exact="influenza" post="along with a positive diagnostic test during the quarantine"/>
 <result pre="with a positive diagnostic test during the quarantine period post" exact="influenza" post="challenge. When evaluating clinical disease, no significant difference in"/>
 <result pre="in all participants receiving the vaccine. After vaccination, but before" exact="influenza" post="challenge, 98 participants (64%) experienced an AE. The number"/>
 <result pre="0 (0) Incidence of adverse events occurring before and after" exact="influenza" post="challenge are summarized here for each group along with"/>
 <result pre="some protection against influenza. At least one other peptide-based universal" exact="influenza" post="vaccine candidate inducing T cell immunity has completed phase"/>
 <result pre="virus shedding and symptoms in a small Phase IB H3N2" exact="influenza" post="human challenge21. In this study single-dose adjuvanted FLU-v was"/>
 <result pre="study represent the healthiest of individuals who could acquire an" exact="influenza" post="infection, are somewhat homogeneous, and the disease demonstrated by"/>
 <result pre="ability to generate antibody responses against the antigens in seasonal" exact="influenza" post="vaccine decreases with age leading to lower efficacy of"/>
 <result pre="The primary endpoint of MMID is a strict definition of" exact="influenza" post="infection and in a typical human population exposed to"/>
 <result pre="influenza infection and in a typical human population exposed to" exact="influenza" post="naturally a broader spectrum of illness would occur, therefore"/>
 <result pre="have low HAI titers after vaccination at the time of" exact="influenza" post="challenge. Overall geometric mean HAI titers did increase after"/>
 <result pre="that these individuals may have a stronger cellular response to" exact="influenza" post="than those who have a strong anti-HA head humoral"/>
 <result pre="strategy employed by FLU-v has potential to offer protection against" exact="influenza" post="infection as a vaccine. These results demonstrate that T"/>
 <result pre="demonstrate that T cell immunity against conserved regions of the" exact="influenza" post="virus is likely to be an important component for"/>
 <result pre="cellular immune response and evaluate how the vaccine interacts with" exact="influenza" post="disease in different cohorts, allowing for informed clinical development"/>
 <result pre="immunity. The need for better, more broadly protective vaccines against" exact="influenza" post="is a high priority worldwide, and few new vaccines"/>
 <result pre="in humans. The efficacy of FLU-v in this wild-type human" exact="influenza" post="challenge study along with the supporting data from previous"/>
 <result pre="of FLU-v will be evaluated against a broader set of" exact="influenza" post="strains and wider spectrum of disease to determine if"/>
 <result pre="that placed them at risk of complication from vaccination or" exact="influenza" post="challenge. Adjuvanted FLU-v or placebo was administered subcutaneously on"/>
 <result pre="to intranasal viral challenge. A total of 107 TCID50 of" exact="influenza" post="challenge virus was delivered intranasally as previously described22. All"/>
 <result pre="and hemodynamically stable, and had two negative diagnostic tests for" exact="influenza" post="on consecutive days. Participants attended follow-up visits on days"/>
 <result pre="viral shedding by an FDA approved clinical testing method for" exact="influenza" post="plus at least one clinical symptom/sign of influenza at"/>
 <result pre="method for influenza plus at least one clinical symptom/sign of" exact="influenza" post="at any time during the inpatient portion of the"/>
 <result pre="Secondary outcome measures included incidence of viral shedding, incidence of" exact="influenza" post="symptoms, incidence of two or more influenza symptoms, total"/>
 <result pre="shedding, incidence of influenza symptoms, incidence of two or more" exact="influenza" post="symptoms, total quantity of symptoms, quantity of viral shedding,"/>
 <result pre="Symptom Severity Assessment Tool, a participant-directed questionnaire designed to assess" exact="influenza" post="disease severity that has been validated in both natural"/>
 <result pre="severity that has been validated in both natural infection and" exact="influenza" post="challenge studies39–41. In addition, a physician assessment was also"/>
 <result pre="for 10 days to determine the presence or absence of" exact="influenza" post="signs/symptoms. Those assessed included arthralgia, chills, conjunctivitis, coryza, diarrhea,"/>
 <result pre="Participants were followed for a total of 63 days post" exact="influenza" post="challenge to identify vaccine-related AEs. Viral detection and quantitation"/>
 <result pre="antigens. Challenge virus A cell-grown, reverse genetics produced wild-type (H1N1)pdm09" exact="influenza" post="A virus was used for intranasal challenge. This GMP-manufactured"/>
 <result pre="no other conflicts of interest. References References 1.ThompsonWWMortality associated with" exact="influenza" post="and respiratory syncytial virus in the United StatesJAMA200328917910.1001/jama.289.2.17912517228 2.StohrKPUBLIC"/>
 <result pre="2.StohrKPUBLIC HEALTH: enhanced: will vaccines be available for the next" exact="influenza" post="pandemic?Science20043062195219610.1126/science.110816515618505 3.CoxRCorrelates of protection to influenza virus, where do"/>
 <result pre="available for the next influenza pandemic?Science20043062195219610.1126/science.110816515618505 3.CoxRCorrelates of protection to" exact="influenza" post="virus, where do we go from here?Hum. Vaccin. Immunother.2013940540810.4161/hv.2290823291930"/>
 <result pre="https://www.cdc.gov/flu/about/burden/2017-2018.htm (2019). 5.RolfesMAet al.Annual estimates of the burden of seasonal" exact="influenza" post="in the United States: a tool for strengthening influenza"/>
 <result pre="seasonal influenza in the United States: a tool for strengthening" exact="influenza" post="surveillance and preparednessInfluenza Other Respir. Viruses20181213213710.1111/irv.1248629446233 6.IulianoADet al.Estimates of"/>
 <result pre="9.YapKLAdaGLMcKenzieIFCTransfer of specific cytotoxic T lymphocytes protects mice inoculated with" exact="influenza" post="virusNature197827323823910.1038/273238a0306072 10.LukacherAEIn vivo effector function of influenza virus-specific cytotoxic"/>
 <result pre="mice inoculated with influenza virusNature197827323823910.1038/273238a0306072 10.LukacherAEIn vivo effector function of" exact="influenza" post="virus-specific cytotoxic T lymphocyte clones is highly specificJ. Exp."/>
 <result pre="clones is highly specificJ. Exp. Med.198416081482610.1084/jem.160.3.8146206190 11.LinYLBiological properties of an" exact="influenza" post="A virus-specific killer T cell clone. Inhibition of virus"/>
 <result pre="of virus replication in vivo and induction of delayed- type" exact="hypersensitivity" post="reactionsJ. Exp. Med.198115422523410.1084/jem.154.2.2256267157 12.JaffePAet al.Kinetics and specificity at the"/>
 <result pre="the clonal level of the cytotoxic T lymphocyte response to" exact="influenza" post="pneumoniaViral Immunol.1987125926610.1089/vim.1987.1.2592855702 13.Ennis, F. A. &amp;amp; Wells, M. A."/>
 <result pre="Allergy Clin. Immunol.198473B910.1016/0091-6749(84)90421-4 15.BenninkJRMurine cytotoxic T lymphocyte recognition of individual" exact="influenza" post="virus proteins. High frequency of nonresponder MHC class I"/>
 <result pre="Med.198716540841610.1084/jem.165.2.4083029268 18.ReayPAJonesIMGotchFMMcMichaelAJBrownleeGGRecognition of the PB1, neuraminidase, and matrix proteins of" exact="influenza" post="virus A/NT/60/68 by cytotoxic T lymphocytesVirology198917047748510.1016/0042-6822(89)90439-X2658303 19.StoloffGACaparros-WanderleyWSynthetic multi-epitope peptides"/>
 <result pre="19.StoloffGACaparros-WanderleyWSynthetic multi-epitope peptides identifiedin silico induce protective immunity against multiple" exact="influenza" post="serotypesEur. J. Immunol.2007372441244910.1002/eji.20073725417668898 20.PleguezuelosORobinsonSStoloffGACaparrós-WanderleyWSynthetic Influenza vaccine (FLU-v) stimulates cell"/>
 <result pre="a double-blind, randomised, placebo-controlled Phase I trialVaccine2012304655466010.1016/j.vaccine.2012.04.08922575166 21.PleguezuelosOet al.A synthetic" exact="influenza" post="virus vaccine induces a cellular immune response that correlates"/>
 <result pre="challenge in humansClin. Vaccin. Immunol.20152282883510.1128/CVI.00098-15 22.MemoliMJet al.Validation of the wild-type" exact="influenza" post="A human challenge model H1N1pdMIST: an a (H1N1)pdm09 dose-finding"/>
 <result pre="Infect. Dis.20146069370210.1093/cid/ciu92425416753 23.AtsmonJet al.Safety and immunogenicity of multimeric-001—a novel universal" exact="influenza" post="vaccineJ. Clin. Immunol.20123259560310.1007/s10875-011-9632-522318394 24.van DoornEet al.Evaluating the immunogenicity and"/>
 <result pre="DoornEet al.Evaluating the immunogenicity and safety of a BiondVax-developed universal" exact="influenza" post="vaccine (Multimeric-001) either as a standalone vaccine or as"/>
 <result pre="as a standalone vaccine or as a primer to H5N1" exact="influenza" post="vaccine: phase IIb study protocolMedicine (Baltimore)201796e633910.1097/MD.000000000000633928296763 25.LeggattGRPeptide dose and/or"/>
 <result pre="young adults immunized with the standard or a high dose" exact="influenza" post="vaccineVaccine2011292865287310.1016/j.vaccine.2011.02.01721352939 32.HanAet al.A dose finding study of a wild-type"/>
 <result pre="influenza vaccineVaccine2011292865287310.1016/j.vaccine.2011.02.01721352939 32.HanAet al.A dose finding study of a wild-type" exact="influenza" post="A/H3N2 virus in a Healthy Volunteer Human Challenge ModelClin."/>
 <result pre="antihemagglutinin and antineuraminidase antibodies as correlates of protection in an" exact="influenza" post="A/H1N1 virus healthy human challenge modelMBio20167e00417-1610.1128/mBio.00417-1627094330 34.Park, J. K."/>
 <result pre="a correlate of protection in a healthy volunteer challenge with" exact="influenza" post="A/H1N1pdm virus. MBio9, 10.1128/mBio.02284-17 (2018). 35.BrydakLBTadeuszSMagdalenaMAntibody response to influenza"/>
 <result pre="with influenza A/H1N1pdm virus. MBio9, 10.1128/mBio.02284-17 (2018). 35.BrydakLBTadeuszSMagdalenaMAntibody response to" exact="influenza" post="vaccination in healthy adultsViral Immunol.20041760961510.1089/vim.2004.17.60915671759 36.GoodwinKViboudCSimonsenLAntibody response to influenza"/>
 <result pre="to influenza vaccination in healthy adultsViral Immunol.20041760961510.1089/vim.2004.17.60915671759 36.GoodwinKViboudCSimonsenLAntibody response to" exact="influenza" post="vaccination in the elderly: a quantitative reviewVaccine2006241159116910.1016/j.vaccine.2005.08.10516213065 37.Sacadura-LeiteESousa-UvaARebelo-de-AndradeHAntibody response"/>
 <result pre="in the elderly: a quantitative reviewVaccine2006241159116910.1016/j.vaccine.2005.08.10516213065 37.Sacadura-LeiteESousa-UvaARebelo-de-AndradeHAntibody response to the" exact="influenza" post="vaccine in healthcare workersVaccine20123043644110.1016/j.vaccine.2011.10.06122064268 38.van DoornELiuHHuckriedeAHakESafety and tolerability evaluation"/>
 <result pre="the Influenza Patient-reported Outcome (FLU-PRO) diary to evaluate symptoms of" exact="influenza" post="viral infection in a healthy human challenge modelBMC Infect."/>
</results>
